Share
280 Posts.
lightbulb Created with Sketch. 25
clock Created with Sketch. 11/09/24
09:52
Share
Originally posted by Eagle0:
↑
Now it's a refrigeration issue lol. If it's not one thing it's something else, hedged by an assurance the sp is going to rerate. I know nothing about NONO-42 except thats its pharmacokinetics differs from both afamelanotide and AGN-007. What I do know its that the scientists and other stakeholders developing these drugs know more than a random poster who pushes 3 main arguments:
Expand
NA-1 CEO recently asked why the fail in phase 3 study. Had nothing to do with half life or prolong exposure but now they are targeting a new drug that is specific for first golden hour after stroke as they see the benefit of the drug will be best seen in first hour. No one saying it won’t work but the class of drug has proven that phase 3 is where it fails
(20min delay)